About the role
About Rezo Therapeutics Rezo is a different kind of biopharma company. Our mission is to dramatically increase the success rate of drug development by building a disease-agnostic, fully-integrated, network biology platform that will redefine our understanding of human disease and ability to treat it. We are leveraging a unique integrated approach, combining capabilities in genetics, proteomics, structural biology and AI to generate deep biological insights and novel therapeutic approaches. Located in San Francisco’s vibrant Mission Bay neighborhood, Rezo is in close proximity to UCSF, numerous urban amenities, and outdoor recreational opportunities. We recognize that realizing our mission depends as much on our people as it does on our science and are building a workplace that fosters collaboration, respect, and diversity where contributing to your team’s success is valued as highly as individual achievements. If you’re passionate about team science and breaking down barriers to progress in drug development, please consider joining us! The Opportunity Rezo is seeking an experienced Director/Senior Director of In Vivo Pharmacology to lead the strategy, design, execution, and interpretation of in vivo pharmacology studies across our oncology portfolio. The successful candidate will bring deep expertise in oncology models, PK/PD-driven study design, translational pharmacology, and cross-functional drug discovery. They will work closely with biology, medicinal chemistry, DMPK, and external CRO partners to generate robust, decision-driving in vivo data packages. This is an opportunity to build and shape the in vivo pharmacology function at a growing oncology biotech, with direct impact on program strategy and portfolio progression. \n Key
Responsibilities: Lead the in vivo pharmacology strategy for Rezo’s small-molecule oncology programs, including study design, model selection, dose/schedule optimization, PK/PD integration, efficacy assessment, and translational interpretation. Design and oversee in vivo studies in CDX, PDX, syngeneic, as appropriate for each program and mechanism. Develop pharmacology plans that support development candidate nomination, IND-readiness, and early clinical translational strategy. Integrate tumor efficacy, exposure, pharmacodynamic biomarkers, tolerability, and mechanism-of-action data to guide compound prioritization and program decisions. Mentor and potentially manage scientists as the organization grows.